Bottom line
Is LYFIX a good fund? The bottom line
LYFIX is a share class of AlphaCentric Life Sciences and Healthcare Fund, an actively managed health care sector mutual fund from Mutual.
Its expense ratio is 1.41% — about $141 a year on every $10,000 invested, more expensive than 78% of health care sector funds we track.
It returned +28.2% over one year, +5.6% a year over five years (as of Dec 31, 2025, per its prospectus).
With $46.6 million in net assets and 62 holdings, its largest position is Gilead Sciences Inc (5.5%) and the top 10 make up 40.7% of the portfolio.
What stands out
- No front-end sales load
What to watch
- Expensive for its category (1.41%)
- Small fund ($46.6 million) — small funds are likelier to close
- High turnover (107% a year) can mean more taxable distributions
Updated Nov 19, 2026
What LYFIX invests in
The Fund?s investment objective is long-term capital appreciation.
The Fund seeks to achieve its investment objective by investing in the life sciences and healthcare related companies that the Fund?s investment sub-advisor, Kennedy Capital Management LLC (the ?Sub-Advisor?), believes have the potential to appreciate in value. Under normal market conditions, the Fund invests at least 80% of its net assets (plus borrowings for investment purposes) in the securities of companies in the life sciences and healthcare sectors , which the Fund defines to be the category of companies related to producing or supplying facilities, supplies, technology, pharmaceuticals, equipment, devices or services for the preservation and care of a person?s or animal?s health . The Fund invests in equity securities, primarily common stock, of these companies and may also invest, from time to time, in exchange traded funds (?ETFs?) that primarily invest in these companies. The…
From the fund's prospectus (filed Jul 28, 2026).
LYFIX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| LYFIX | +28.2% | +5.6% | — |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2025
What LYFIX costs
On a $10,000 investment, LYFIX's 1.41% expense ratio costs about $141 a year. The prospectus estimates $2,357 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
LYFIX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Gilead Sciences Inc | 5.53% |
| 2 | Vertex Pharmaceuticals Inc | 5.33% |
| 3 | Astrazeneca Plc | 4.63% |
| 4 | First American Funds Inc | 4.26% |
| 5 | Roivant Sciences Ltd | 3.67% |
| 6 | Argenx Se | 3.59% |
| 7 | Neurocrine Biosciences Inc | 3.51% |
| 8 | Incyte Corp | 3.51% |
| 9 | Axsome Therapeutics Inc | 3.43% |
| 10 | Apogee Therapeutics Inc | 3.28% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 40.7% of the fund. See all top 25 holdings and asset mix →